Clinical trials
Treatment clinical trials
Below are recruiting treatment clinical trials, each written for real people, not researchers. We’re tracking 8,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07495215RecruitingPhase 1/Phase 2
Personalized mRNA vaccine plus immunotherapy for liver cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
Hangzhou, ZhejiangAges 18–75 - NCT07490041RecruitingEarly Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Hangzhou, ZhejiangAges 5 years+ - NCT07491016Recruiting
Telitacicept plus baricitinib for hard-to-treat rheumatoid arthritis
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
Hangzhou, ZhejiangAges 18–85 - NCT07490600Recruiting
Testing brain stimulation and rewards for quitting cocaine
This trial combines deep transcranial magnetic stimulation (TMS) with a reward program (contingency management) to help people stop using cocaine. It may help if you are struggling with moderate to severe cocaine use and want a non-drug treatment.
Houston, TexasAges 18–65 - NCT07493109RecruitingPhase 3
Maintenance treatment for hepatitis B-related lymphoma after initial therapy
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Changchun, JilinAges 18–80 - NCT07491146RecruitingPhase 2
Study of HSK55718 for pain after abdominal surgery
This trial tests a new medicine, HSK55718, to see if it safely reduces pain after planned abdominal surgery. It is for adults who have moderate or severe pain after surgery and are otherwise in good health.
Changsha, HunanAges 18 years+ - NCT07491913Recruiting
Stopping biologic therapy for Takayasu arteritis in stable patients
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
IstanbulAges 18 years+ - NCT07493824RecruitingPhase 4
Study of Paiteling Antibacterial Liquid for Persistent HPV Infection
This trial tests an antibacterial liquid (Paiteling®) to see if it can clear a persistent high-risk HPV infection of the cervix. It may be an option for women whose HPV has lasted 2 years or more and whose cervical biopsy shows only mild changes.
Changchun, JilinAges 26–65 - NCT07497919RecruitingPhase 2
Combination therapy for EGFR-positive advanced penile cancer
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
ShanghaiAges Any age - NCT07490717Enrolling by invitation
Treating PTSD and opioid use in jails
This study tests new ways to screen and treat people in jail who have both post-traumatic stress disorder (PTSD) and opioid use disorder. It aims to help participants with therapy while incarcerated and after release.
Little Rock, ArkansasAges 18 years+ - NCT07495397Recruiting
Daphnetin plus chemo for advanced ovarian cancer maintenance
This trial is testing a combination of two drugs—daphnetin capsules and a standard chemotherapy (TC regimen)—as a targeted maintenance therapy after initial surgery for advanced ovarian cancer. The goal is to see if this treatment can help keep the cancer from coming back.
Changchun, JilinAges 18–75 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT07493135RecruitingEarly Phase 1
IMV102 for relapsed/refractory multiple myeloma
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
BeijingAges 18–80 - NCT07498478RecruitingPhase 2
Tinengotinib and fulvestrant for advanced HR+ HER2- breast cancer
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07491445RecruitingPhase 3
Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+ - NCT07494305RecruitingPhase 2
Testing a new drug for bipolar depression
This trial tests an investigational drug called LB-102 for people with bipolar I disorder who are currently experiencing a major depressive episode without psychosis. It aims to see if the drug is safe and effective for treating depression symptoms.
Bentonville, ArkansasAges 18–65 - NCT07496229RecruitingPhase 1/Phase 2
Testing a new drug combo for T-cell lymphoma
This trial is testing two drugs together: GW5282 and golidocitinib. It aims to see if this combination can help people with a type of T-cell lymphoma called PTCL. The trial is for patients who have already received other treatments or where standard options are limited.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07496372RecruitingPhase 3
Stem cell injection for advanced heart failure
This trial tests a treatment made from stem cells that are turned into heart muscle cells and injected directly into the heart. It is for people with advanced heart failure who are already on the best available medicines and who are scheduled to have bypass surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT06456359RecruitingPhase 2
Pasireotide maintenance for synovial sarcoma and DSRCT
This trial tests a drug called pasireotide as a maintenance therapy (given after standard treatment to keep cancer from coming back) for people with specific types of sarcoma. It's for patients whose tumors show high levels of certain proteins (SSTR) and who have stable or better disease after standard treatment.
Heidelberg, Baden-WurttembergAges 13–50 - NCT06179524RecruitingPhase 2
CAR-T-19 for CD19-positive B-ALL in children and young adults
This trial tests a new type of immunotherapy called CAR-T-19 for children and young adults up to age 25 whose B-ALL has returned or is not responding to standard treatments. The CAR-T cells are engineered to find and destroy leukemia cells that have the CD19 protein.
TianjinAges Up to 25 years - NCT06085300Recruiting
Bilingual treatment study for children with language delays
This study looks at how bilingual children with language delays respond to treatment in English or Spanish. It aims to find the best way to help them improve their language skills.
Houston, TexasAges 4–6 - NCT05796739Recruiting
Stress testing once or only when needed for high calcium risk
This study compares two approaches to stress testing in people who feel fine but have high coronary artery calcium on a scan. It may help determine whether testing routinely is better than doing it only if symptoms or concerns arise.
SeoulAges 19 years+ - NCT06233838Recruiting
Hemoperfusion study for kidney patients on dialysis
This trial tests a special blood-filtering treatment (hemoperfusion) for people with advanced kidney disease on regular dialysis. It aims to remove harmful substances that standard dialysis may not fully clear.
Fuzhou, FujianAges 18 years+
Hear when a new Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for treatment?
- Yes. Clin2 currently lists 8,322 recruiting treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.